Lexicon Pharmaceuticals Files 8-K on Financials
Ticker: LXRX · Form: 8-K · Filed: Aug 1, 2024
Sentiment: neutral
Topics: financial-condition, results-of-operations, filing
Related Tickers: LXRX
TL;DR
Lexicon Pharma dropped an 8-K on Aug 1st detailing their financial condition. Check it out.
AI Summary
Lexicon Pharmaceuticals, Inc. filed an 8-K on August 1, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the report period ending on August 1, 2024. The company is incorporated in Delaware and headquartered in The Woodlands, Texas.
Why It Matters
This 8-K filing provides investors with an update on Lexicon Pharmaceuticals' financial performance and condition, which is crucial for evaluating the company's current health and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not indicate any immediate or significant risks.
Key Players & Entities
- LEXICON PHARMACEUTICALS, INC. (company) — Registrant
- August 1, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- The Woodlands, Texas (location) — Principal executive offices
- 281-863-3000 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Lexicon Pharmaceuticals, Inc.'s Results of Operations and Financial Condition, and to include Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on August 1, 2024.
In which state is Lexicon Pharmaceuticals, Inc. incorporated?
Lexicon Pharmaceuticals, Inc. is incorporated in Delaware.
What is the business address of Lexicon Pharmaceuticals, Inc.?
The business address of Lexicon Pharmaceuticals, Inc. is 2445 Technology Forest Blvd., 11th Floor, The Woodlands, Texas 77381.
What is the SEC file number for Lexicon Pharmaceuticals, Inc.?
The SEC file number for Lexicon Pharmaceuticals, Inc. is 000-30111.
Filing Stats: 510 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-08-01 16:05:23
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 LXRX The Nasdaq Global Select Market
Filing Documents
- lxrx-20240801.htm (8-K) — 24KB
- pressreleaseearningsq208-0.htm (EX-99.1) — 92KB
- 0001062822-24-000043.txt ( ) — 249KB
- lxrx-20240801.xsd (EX-101.SCH) — 2KB
- lxrx-20240801_lab.xml (EX-101.LAB) — 21KB
- lxrx-20240801_pre.xml (EX-101.PRE) — 12KB
- lxrx-20240801_htm.xml (XML) — 3KB
02 Results of Operation and Financial Condition
Item 2.02 Results of Operation and Financial Condition On August 1, 2024, we issu ed a press release to report our financial results for the quarter ended June 30, 2024. A copy of the press release is attached to this current report on Form 8-K as Exhibit 99.1. The information in this Form 8-K and the Exhibit attached to this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 — Press Release of Lexicon Pharmaceuticals, Inc. dated August 1 , 2024 EX-104 — Cover Page Interactive Data File (embedded within the Inline XBRL document)
Signatures
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Lexicon Pharmaceuticals, Inc. Date: August 1, 2024 By: /s/ Brian T. Crum Brian T. Crum Senior Vice President and General Counsel